Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Lead the technology vision of a high-potential AI and digital venture platformBuild scalable products and tech capabilities in an entrepreneurial settingAbout Our ClientOur client is an entrepreneurial investment platform focused on building and scaling companies in